Perifollicular Xanthomas Associated With Epidermal Growth Factor Receptor Inhibitor Therapy
January 2010
in “
Acta Dermato Venereologica
”
Studysummary This report details a case of a 43-year-old woman developing yellowish papular eruptions alongside typical acneiform skin reactions on her cheeks and chest following a switch from cetuximab to panitumumab treatment.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reported a case of a 43-year-old woman who developed perifollicular xanthomas, characterized by a yellowish papular eruption, during a treatment change from cetuximab to panitumumab, both of which are epidermal growth factor receptor (EGFR) inhibitors. EGFR inhibitors are commonly used in the treatment of various solid tumors due to their role in cell proliferation, differentiation, and angiogenesis. However, these inhibitors often cause cutaneous side effects, including acneiform skin reactions, xerosis, and changes in hair and nails, due to EGFR expression in normal epidermis and associated structures.
